Xgeva 120 mg

Xgeva is a medication containing the active ingredient Denosumab, a monoclonal antibody that works by inhibiting the RANKL protein, which is responsible for activating cells that break down bone tissue.

The medication helps reduce bone loss and prevent skeletal-related complications associated with certain types of cancer. It is also used to treat specific bone tumors and elevated calcium levels in the blood.

Indications

• Prevention of skeletal-related events, such as pathological fractures and spinal cord compression, in patients with multiple myeloma.

• Prevention of skeletal-related complications in patients with solid tumors that have spread to the bones.

• Treatment of Giant Cell Tumor of Bone in adults and skeletally mature adolescents when surgery is not possible or may cause severe complications.

• Treatment of hypercalcemia of malignancy in patients who have not responded to bisphosphonate therapy.

Dosage and Administration

• Usual dose for patients with bone metastases and multiple myeloma: 120 mg once every 4 weeks.

• For Giant Cell Tumor of Bone: 120 mg every 4 weeks, with additional doses on days 8 and 15 of the first month.

• For hypercalcemia of malignancy: 120 mg every 4 weeks, with additional doses on days 8 and 15 of the first month.

• Administered by subcutaneous injection into the upper arm, thigh, or abdomen by a healthcare professional.

• The physician may prescribe calcium and vitamin D supplements to prevent low blood calcium levels, unless calcium levels are elevated.

Warnings and Precautions

• May cause severe hypocalcemia (low blood calcium levels), and any existing calcium deficiency must be corrected before starting treatment.

• Blood calcium levels should be monitored regularly, especially in patients with severe kidney impairment.

• May cause osteonecrosis of the jaw. A dental examination is recommended before treatment, and invasive dental procedures should be avoided whenever possible during therapy.

• May increase the risk of atypical femoral fractures.

• Multiple vertebral fractures may occur after discontinuation of treatment. Therefore, treatment should not be stopped without consulting a physician.

• Elevated calcium levels may occur after discontinuation, particularly in patients with Giant Cell Tumor of Bone.

• Contraindicated in patients with uncorrected hypocalcemia or known severe hypersensitivity to Denosumab.

• May harm an unborn baby. Pregnancy should be avoided during treatment and for at least 5 months after the last dose.

• Should not be used simultaneously with any other medication containing Denosumab.

Possible Side Effects

• Fatigue and general weakness.

• Nausea.

• Diarrhea or constipation.

• Back, joint, and limb pain.

• Headache.

• Low calcium and phosphate levels in the blood.

• Anemia.

• Swelling of the extremities.

• Decreased appetite.

• Skin rash.

• Shortness of breath.

• Osteonecrosis of the jaw or atypical femoral fractures, which are serious complications requiring medical evaluation.

• Severe allergic reactions in rare cases.

Note: Xgeva is a prescription medication that must be used under the supervision of a qualified healthcare professional. Calcium levels and dental health should be monitored throughout treatment. The medication should not be discontinued, and dosing schedules should not be adjusted without consulting a physician.